Curasan
Private Company
Funding information not available
Overview
Curasan is a commercial-stage biomaterials company with a legacy dating back to 1988, focused on bone grafting and tissue regeneration. It markets a portfolio of dental and orthopedic products, primarily based on its proprietary β-tricalcium phosphate technology, which are sold in approximately 50 countries. The company is headquartered in Frankfurt, Germany, with a U.S. subsidiary, and is led by a management team with deep experience in medtech turnarounds and commercialization. Its strategic direction includes expanding its global commercial footprint and advancing a growth factor research spin-off, novaxomx.
Technology Platform
Proprietary synthesis of high-purity β-tricalcium phosphate (β-TCP) for bone graft substitutes, formulated into various product forms (granules, foam, moldable composites). Research into exosome-based growth factors via spin-off novaxomx.
Opportunities
Risk Factors
Competitive Landscape
Curasan competes in the fragmented bone graft substitute market against major players like Zimmer Biomet (Geistlich), Stryker, Medtronic, and Baxter, as well as numerous specialized biomaterial companies. Its differentiation is based on the claimed high purity of its synthetic β-TCP and its specialized product forms for handling. The competitive threat is significant given the marketing power and broad portfolios of its larger rivals.